CRISPR Therapeutics AG
CRSP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $3,320 | $4,959 | $3,160 | $5,755 |
| - Cash | $298 | $389 | $212 | $923 |
| + Debt | $224 | $239 | $244 | $225 |
| Enterprise Value | $3,246 | $4,808 | $3,193 | $5,057 |
| Revenue | $35 | $370 | $0 | $913 |
| % Growth | -90.5% | 84,762.4% | -100% | – |
| Gross Profit | -$75 | $240 | -$110 | $812 |
| % Margin | -215% | 64.8% | -25,186.7% | 88.9% |
| EBITDA | -$447 | -$203 | -$649 | $391 |
| % Margin | -1,278% | -54.8% | -148,850.7% | 42.9% |
| Net Income | -$366 | -$154 | -$650 | $378 |
| % Margin | -1,046.4% | -41.5% | -149,122.7% | 41.4% |
| EPS Diluted | -4.34 | -1.94 | -8.36 | 4.7 |
| % Growth | -123.7% | 76.8% | -277.9% | – |
| Operating Cash Flow | -$143 | -$260 | -$496 | $539 |
| Capital Expenditures | -$2 | -$9 | -$37 | -$82 |
| Free Cash Flow | -$145 | -$270 | -$533 | $457 |